Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JNJ-67484703 multiple-dose tissue-response study in rheumatoid arthritis, ulcerative colitis, and Sjögren’s syndrome
ISRCTN31164692Phase 2Completed
- Sponsor
- University of Birmingham
- Start
- Sep 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Phase 2, open-label trial of JNJ-67484703 in rheumatoid arthritis (RA), autoimmune colitis and Sjögren's syndrome (6 arms), sponsored by University of Birmingham. Primary endpoint: Biological effects in disease-relevant tissues. Started Sep 2022; status: completed.
02
Drugs
JNJ-67484703
03
Conditions
rheumatoid arthritis (RA)autoimmune colitisSjögren's syndrome
Beyond the preview
Go deeper on ISRCTN31164692.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN31164692.